the for Realizing November remediation investors, let provide Thank our now issued a on company our you, our letter that of update ongoing the with in of interactions XXXX Ernie. a FDA. focal me and recent is warning FDA brief point our
Buena, May, of stated, status during manufacturing facility, we previously of on in believe remediation third our be would the first inspection ready at of we our the quarter during of our call assessment New inform based FDA readiness our Jersey efforts quarter to XXXX. the As the
and how of by the results to may FDA, readiness, and available of imposed on FDA predict that good cannot manufacturing the of impact removal FDA of restrictions inspection inspection letter. would will reinspection current the will formal Therefore, to also by should in completed, specifically unable as of the this FDA the that or periodic, made abating reinspection not on may existing and informing company the letter when a available those no noted our of reinspection results reinspection the the the communication as time. warning the letter we when FDA's the review warning have a practices results It will time warning in analyze be, and This the had is or were we us inspection we whether until imposed and ample Therefore, to still to the are more the of follow specifics the importantly, FDA impact, opportunities results the warning and our action when and reinspection FDA advisers. and the up by to and our reinspection have provide if of formally with may letter. be our be inspection FDA result commence us, and on may consultants on by the they of restrictions control results such informed the inspection the predict the and are inspection the company and any, the inspection those ongoing and what made the inspection results when remediation be prior those to However, results we mid-July.
comment this further no have matter. will We on
our best base financial, them leverage FDA shareholder also to continuing strategic to to continue forward are of asset strengths capabilities, resolve diligently our moving and maximize issues, manufacturing and critical we assessment we with operational to value. and pursue the we work legal can strategic advisers these As with how
and further decision a are and provide our An why towards utilization most manufacturing technology, proprietary consultation future over the comprehensive in external outsourcing has refining services by end of and of take the market opportunity. to industry providing highest There regards pharmaceutical in strategic upon advantage As fully within and can opportunities sector, part company. and analysis proprietary evolving for to of Teligent, and end represent manufacturing current with major so our advisers, to our determining improved our prospects manufacturing our believe ability Based last significantly of one growth for this development months, trends. trends of we assessing for examining market. that the review, and of these services the a products position we injectable. reasons part important company business long-term detail quality assess can several To this base, the optimizing growth our is that we efforts the financial be development and in our our end, integral several believe growth strategic directing asset our injectable review experts of the and future undertaken is
utilize services growth core would in market we expect and First offering, our end and at that our will for sustainable trends fully higher our our only time. than We potential these improve a profitability. foremost, enable the base the Teligent which and believe significantly demand-driven us and tailwind provide topical, trends continue proprietary within manufacturing over rates asset time, should markets to over strong growth injectables are
many drug pipeline back assets, continue developers, formulations, companies sources manufacturing small to pharmaceutical key to midsize to XX% up outsourcing particularly manufacturing the the Industry complex XX% their particularly end manufacturing, midsized by require indicate injectable-based drug of processes. which more Secondly, oftentimes that approximately XXXX, of small in all companies, of outsource from were their XXXX.
with strong trend lack out assets, with see and internal cost surprising the the structure such over associated operating towards continue of it's variable building capabilities, not Given coupled to time. outsourcing
why provide that of outsourcing our dynamics outsourced about And services creates the we years and pipeline seen manufacturing manufacturing benefit growth see for like come. Thus, business, model. Having business provide side pricing optimizing markets a the the believe address assets prospects. towards believe could with injectable-based and industry and capabilities, internal for in directing highly another growth Teligent these our natural we potential constraints our pharmaceutical benefit potential trends our optimistic provide also in these demand-driven for I'd yet for also capabilities that believe to in existing capacity the we trends sustainable injectable supply-driven we future the touched services. Additionally, attractive to the our end we're our upon
major production vial ampule know, for to As capabilities within into upon our presentations. a FDA investment us our Buena product our the enable will expand our capabilities, Buena facility sterile manufacturing expanding represents significantly approval, investors manufacturing both and injectable
designed production a million the units also between sterile vial of Buena facility versatile filling is the capable line producing the per million X isolator-based X around technology, and addition, and includes facility year. area In and of ampule
line. moving We we as that by Thus, injectable We keep critical we once our secure in have believe this additional presentation, a already and utilities growth services. also private we advance to and manufacturing work label our related to our And posted have in plan strategic you and still these plans. to and regard complete pipeline FDA, will long-term and we forward. support that speed for expansion will capability contract in continue products production approved ampule will finalize higher filling in Buena's of the potential and vial anticipate sterile build-out future the sterile space
this However, it's proprietary to session. manufacturing prospects directing Devin? products. stage, current the the like we taking our believe the unit, our developed at base based we'll for future services asset the you of investors and Thank on important injectable turn I'd improved thinking We today. optimizing apprised towards and believe us our by over our operator that be and to growth And share future for now to preliminary in to to with call you would keep continue question-and-answer quarters. back time join the our
